Introduction

EuroNanoMed (ENM) is an ERA-NET on Nanomedicine established since 2008 as a platform for funding agencies and ministries to coordinate research and innovation programmes with the goal of creating and funding collaborative research and innovation projects that can convert research in nanotechnology into practical gains in medicine.

Call with two stages:

Preposal Stage: Deadline 16/01/2018

Full Proposal Stage: Deadline 30/05/2018

Aim of the Call

The aims of the call are:

• To support translational research projects that combine innovative approaches in the field of nanomedicine and;
• To encourage and enable transnational collaboration between public and private research groups from academia (research teams from universities, higher education institutions, public research institutions) and clinical/public health research (research teams from hospital/ public health, healthcare settings and other healthcare organisations) or research teams from industrial enterprises (all size). The participation of Medical Doctors and SMEs (Small and Medium-size Enterprises) is strongly encouraged.

Topics of the Call

Project proposals will address multidisciplinary and translational research. The project proposals must cover at least one of the following areas that are equal in relevance for this call:

1. Regenerative medicine

2. Diagnostics

3. Targeted delivery systems

Applicants are asked to specify to which of the two categories described below the project falls, according to its TRL, degree of innovation and expected time to market:

• Innovation applied research projects: Proof of concept projects for innovative applications with analytical/experimental research and/or implementation and integration of components and test in laboratory and/or animal models. Safety and nanotoxicity should be taken into account when relevant. The viability of a path that may lead the experimental and/or analytical results (for TRL 3) and/or demonstrators (for TRL 4) to a future application at medium/long term shall also be demonstrated.
• Projects with high potential of applicability at short/medium term: Projects closer to the market for the validation of demonstrators and prototypes in a realistic laboratory (for TRL 5) and/or relevant simulated operational field environment (for TRL-6). The viability of a path that may lead the validated systems and results to real products shall be demonstrated. Industrial engagement is crucial in this type of projects. Medical regulatory aspects have to be properly considered.

General Conditions for application

Joint research proposals may be submitted by applicants belonging to one of the following categories:

• Academia (research teams working in universities, other higher education institutions) or research institutes;
• Clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations). Participation of Medical Doctors is encouraged;
• Enterprise (private companies of all sizes). Participation of Small and Medium-size Enterprises (SMEs) is encouraged.

Each application should include partners from at least two of the three categories A, B and C. Each consortium submitting a proposal must involve a minimum of three eligible and a maximum of five eligible partners from at least three different countries participating to the. The maximum number of partners can be increased from five to seven under certain circumstances. No more than two eligible partners from the same country participating in the call will be accepted in one consortium.

Please note! Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual EuroNanoMed funding organization respective of the country/region from which applicants have applied. The applications are therefore subjected to eligibility criteria of individual funding organizations. Please note that the national eligibility conditions have evolved since the last EuroNanoMed call.

Spanish Funding Institutions are:

CDTI- for companies

Agencia Estatal de Investigación- Academic Entities

Instututo Carlos III- Clinical Entities

Funding for Spanish Clinical Entities:

Up to 150.000 € per partner (overheads included,21%)

Up to 200.000 € per coordinator (overheads included, 21%)

If the Cklinical Entity participates as  partner, personnel costs are not elegible.